Deciphera Pharmaceuticals Llc Stock Total Asset

DCPHDelisted Stock  USD 13.32  0.36  2.63%   
Deciphera Pharmaceuticals LLC fundamentals help investors to digest information that contributes to Deciphera Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Deciphera Stock. The fundamental analysis module provides a way to measure Deciphera Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Deciphera Pharmaceuticals stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Deciphera Pharmaceuticals LLC Company Total Asset Analysis

Deciphera Pharmaceuticals' Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.

Total Asset

 = 

Tangible Assets

+

Intangible Assets

More About Total Asset | All Equity Analysis

Current Deciphera Pharmaceuticals Total Asset

    
  473.57 M  
Most of Deciphera Pharmaceuticals' fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Deciphera Pharmaceuticals LLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
Competition

Based on the latest financial disclosure, Deciphera Pharmaceuticals LLC has a Total Asset of 473.57 M. This is 93.7% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The total asset for all United States stocks is 98.39% higher than that of the company.

Deciphera Total Asset Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Deciphera Pharmaceuticals' direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Deciphera Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Deciphera Pharmaceuticals by comparing valuation metrics of similar companies.
Deciphera Pharmaceuticals is currently under evaluation in total asset category among its peers.

Deciphera Fundamentals

About Deciphera Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Deciphera Pharmaceuticals LLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Deciphera Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Deciphera Pharmaceuticals LLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Other Consideration for investing in Deciphera Stock

If you are still planning to invest in Deciphera Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Deciphera Pharmaceuticals' history and understand the potential risks before investing.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Transaction History
View history of all your transactions and understand their impact on performance
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Commodity Directory
Find actively traded commodities issued by global exchanges
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance